Neuregulin as a heart failure therapy and mediator of reverse remodeling

Current Heart Failure Reports

Volumn 11, Issue 1, 2014, Pages 40-49

  Galindo, Cristi L ^a   Ryzhov, Sergey ^a   Sawyer, Douglas B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac remodeling; ErbB2; ErbB3; ErbB4; GGF2; Neuregulin

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ANGIOGENESIS; ARTICLE; CARDIOVASCULAR PROCEDURE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIABETIC CARDIOMYOPATHY; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; FIBROBLAST; HEART FAILURE; HEART FAILURE THERAPY; HEART FUNCTION; HEART MUSCLE CELL; HEART STRESS; HEMATOPOIETIC CELL; HUMAN; IMMUNOCOMPETENT CELL; INTERSTITIUM; INTRACELLULAR SIGNALING; ISCHEMIC CARDIOMYOPATHY; MEDIATOR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL STRESS; SYSTOLIC HEART FAILURE; VASCULARIZATION;

BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84896725049     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0176-2     Document Type: Article

References (108)

1. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386-90.
2. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14-30. (Pubitemid 36335807)
3. Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res. 2012;9:178-83.
4. Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L, et al. Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci. 2013;33:7856-69.
5. Mendes-Ferreira P, De Keulenaer GW, Leite-Moreira AF, Bras-Silva C. Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discov Today. 2013;18:836-42.
6. Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. Circ Res. 2012;111:1376-85.
7. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 2003;35:1473-9. (Pubitemid 37491190)
8. Chen M, Bi LL, Wang ZQ, Zhao F, Gan XD, Wang YG. Time-dependent regulation of neuregulin-1beta/ErbB/ERK pathways in cardiac differentiation of mouse embryonic stem cells. Mol Cell Biochem. 2013;380:67-72.
9. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998;273:28238-46. (Pubitemid 28496122)
10. Clement CM, Thomas LK, Mou Y, Croslan DR, Gibbons GH, Ford BD. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res. 2007;44:303-12. (Pubitemid 46956833)
11. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999;277:H2205-11.
12. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol. 2006;41:845-54. (Pubitemid 44635571)
13. Fukazawa T, Matsumoto M, Imura T, Khalesi E, Kajiume T, Kawahara Y, et al. Electrical stimulation accelerates neuromuscular junction formation through ADAM19/neuregulin/ErbB signaling in vitro. Neurosci Lett. 2013;545:29-34.
14. Kasasbeh, E., Murphy, A., Ahmad, F.A., Tu, E., Williams, P., Nunnally, A., et al. Neuregulin-1β improves cardiac remodeling after myocardial infarction in swine. Circulation. 2011;124:Abstract 15531.
15. Pentassuglia L, Sawyer DB. ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions. Biochim Biophys Acta. 2013;1833:909-16.
16. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551-4. (Pubitemid 34297631)
17. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol. 1999;277:H2026-37.
18. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279:51141-7. (Pubitemid 40017856)
19. Zhao YY, Sawyer DB, Baliga RR, Opel DJ, Han X, Marchionni MA, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261-9. (Pubitemid 28227629)
20. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228-35. (Pubitemid 44080212)
21. Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation. 2004;109:324-6. (Pubitemid 38133898)
22. Brero A, Ramella R, Fitou A, Dati C, Alloatti G, Gallo MP, et al. Neuregulin-1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res. 2010;88:443-52.
23. •• Ebner B, Lange SA, Eckert T, Wischniowski C, Ebner A, Braun-Dullaeus RC, et al. Uncoupled eNOS annihilates neuregulin-1beta-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction. Mol Cell Biochem. 2013;373:115-23. This study made the interesting observation that NRG administered during ischemia and prior to reperfusion increases infarct size. It went on to show that this effect is due to enhancing ROS formation by activating uncoupled nitric oxide synthase (NOS). Either removing eNOS or improving coupling through coadministration of L-arginine as a substrate for eNOS converted NRG to a cardioprotective lingand, likely through GSK3β inactivation.
24. Gu X, Liu X, Xu D, Li X, Yan M, Qi Y, et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res. 2010;88:334-43.
25. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol Heart Circ Physiol. 1999;277:H2026-37.
26. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res. 2005;311:135-46. (Pubitemid 41527182)
27. Lebrasseur NK, Cote GM, Miller TA, Fielding RA, Sawyer DB. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol. 2003;284:C1149-55.
28. Xu Z, Ford GD, Croslan DR, Jiang J, Gates A, Allen R, et al. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis. 2005;19:461-70. (Pubitemid 40968059)
29. Shyu WC, Lin SZ, Chiang MF, Yang HI, Thajeb P, Li H. Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol Aging. 2004;25:935-44. (Pubitemid 38813173)
30. Xu Z, Jiang J, Ford G, Ford BD. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun. 2004;322:440-6. (Pubitemid 39490323)
31. • Hedhli N, Dobrucki LW, Kalinowski A, Zhuang ZW, Wu X, Russell 3rd RR, et al. Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. Cardiovasc Res. 2012;93:516-24. These investigators defined a role for endothelial-derived NRG as an important mediator of ischemia-induced angiogenesis in peripheral vascular disease. These findings have clear therapeutic implications that have yet to be explored.
32. •• Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123:2254-62. These investigators used endothelial-specific ablation of NRG to demonstrate a role for endogenous cardiac NRG in the protection of the heart from ischemic injury. The elegant work sets the stage to explore how endogenous and exogenous recombinant neuregulin might be used to enhance recovery from myocardial infarction.
33. Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res. 2009;315:1302-12.
34. Fang SJ, Wu XS, Han ZH, Zhang XX, Wang CM, Li XY, et al. Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Chin Med J (Engl). 2010;123:3597-604.
35. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation. 1999;100:407-12. (Pubitemid 29362412)
36. Gui C, Zhu L, Hu M, Lei L, Long Q. Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy. Cardiovasc Pathol. 2012;21:414-20.
37. Rohrbach S, Niemann B, Silber RE, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol. 2005;100:240-9. (Pubitemid 41348815)
38. Peng X, Guo X, Borkan SC, Bharti A, Kuramochi Y, Calderwood S, et al. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem. 2005;280:13148-52.
39. Geisberg C, Pentassuglia L, Sawyer DB. Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep. 2012;9:211-8.
40. Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. The significance of oncogene amplification in primary breast cancer. Int J Cancer. 1989;43:270-2. (Pubitemid 19062423)
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
42. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-21. (Pubitemid 34177427)
43. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr. CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84. (Pubitemid 41464706)
44. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. (Pubitemid 41464705)
45. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859-65. (Pubitemid 47477261)
46. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100:684-92.
47. Davis M, Witteles RM. Cardiac testing to manage cardiovascular risk in cancer patients. Semin Oncol. 2013;40:147-55.
48. Liu X, Gu X, Li Z, Li X, Li H, Chang J, et al. Neuregulin-1/erbB- activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438-47. (Pubitemid 44436803)
49. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009;138:257-70.
50. Bian Y, Sun M, Silver M, Ho KK, Marchionni MA, Caggiano AO, et al. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol. 2009;297:H1974-83.
51. Guo YF, Zhang XX, Liu Y, Duan HY, Jie BZ, Wu XS. Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure. Chin Med J (Engl). 2012;125:807-14.
52. • Hill MF, Patel AV, Murphy A, Smith HM, Galindo CL, Pentassuglia L, et al. Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1beta improves left ventricular function, gene and protein expression in rats after myocardial infarction. PLoS One. 2013;8:e55741. In this study, the effects of recombinant NRG were examined in a rat model of cardiac remodeling after myocardial infarction and were found to improve cardiac function in concert with suppressing/reversing a number of the protein and gene expression changes that occur in chronic heart failure.
53. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol. 2011;10:69.
54. Xiao J, Li B, Zheng Z, Wang M, Peng J, Li Y, et al. Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction. Coron Artery Dis. 2012;23:460-8.
55. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907-14.
56. •• Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83-92. In this clinical trial, the investigators define the hemodynamic response to recombinant NRG, showing its inodilator properties. Interestingly, the treatment was associated with improved myocardial function chronically that was most pronounced in the intermediate dose group.
57. Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T, et al. Serum neuregulin-1beta as a biomarker of cardiovascular fitness. Open Biomark J. 2009;2:1-5.
58. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120:310-7.
59. Geisberg CA, Wang G, Safa RN, Smith HM, Anderson B, Peng XY, et al. Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22:577-82.
60. Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, et al. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J Card Fail. 2013;19:10-5.
61. •• Zeng, Z., Gui, C., Nong, Q., Du, F., Zhu, L. Serum neuregulin-1beta levels are positively correlated with VEGF and Angiopoietin-1 levels in patients with diabetes and unstable angina pectoris. Int J Cardiol. 2013. On the basis of animal studies, one might predict that NRG is released by ischemia, even before myocardial injury. These authors measured serum NRG in patients with unstable angina and provide evidence to support this idea. The potential of NRG as a biomarker of ischemia is further supported by Ref. 50.
62. Huertas-Vazquez A, Teodorescu C, Reinier K, Uy-Evanado A, Chugh H, Jerger K, et al. A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death. Heart Rhythm. 2013;10:994-8.
63. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877-92. (Pubitemid 135750519)
64. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet. 2003;72:83-7. (Pubitemid 36056844)
65. Nicodemus KK, Luna A, Vakkalanka R, Goldberg T, Egan M, Straub RE, et al. Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol Psychiatry. 2006;11:1062-5. (Pubitemid 44863428)
66. Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:96-101. (Pubitemid 43062550)
67. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, et al. Sudden death in psychiatric patients. Br J Psychiatry. 1998;172:331-6. (Pubitemid 28183860)
68. Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. J Clin Psychiatry. 2011;72:936-41.
69. Carraway 3rd KL, Burden SJ. Neuregulins and their receptors. Curr Opin Neurobiol. 1995;5:606-12.
70. Galindo, C., Truc-Tran, L., Ryzhov, S., Feoktistov, I., Sawyer, D.B. Neuregulin-1β Inhibits TGFβ-induced Cardiofibroblast to Myofibroblast Transition. Cardiovasc Res. 2013;113:Abstract 302.
71. Brittain, E., Muldowney, J., Geisberg, C., Caggiano, A., Eisen, A., Anderson, S., et al. Evaluation of cardiac function in symptomatic heart failure patients in a single infusion, Phase 1, dose escalation study of glial growth factor 2. J Am Coll Cardiol. 2013;61.
72. Lenihan, D.J., Anderson, S., Geisberg, C., Caggiano, A., Eisen, A., Brittain, E., et al. Safety and tolerability of glial growth factor 2 in patients with chronic heart failure: a phase I single dose escalation study. J Am Coll Cardiol. 2013;61.
73. Odiete O, Konik EA, Sawyer DB, Hill MF. Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1beta/ErbB in response to myocardial infarction resulting in worsening heart failure. Cardiovasc Diabetol. 2013;12:52.
74. Miller TA, Icli B, Cote GM, Lebrasseur NK, Borkan SC, Pimentel DR, et al. Palmitate alters neuregulin signaling and biology in cardiac myocytes. Biochem Biophys Res Commun. 2009;379:32-7.
75. •• Jay SM, Murthy AC, Hawkins JF, Wortzel JR, Steinhauser ML, Alvarez LM, et al. An engineered bivalent neuregulin protects against Doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013;128:152-61. These investigators engineered NRG to favor ErbB4 or ErbB3 homodimer formation, with the goal of removing ErbB2 activation during NRG stimulation. They provide intriguing evidence that such an approach can protect the heart and limit tumor growth.
76. Force T, Wang Y. Mechanism-based engineering against anthracycline cardiotoxicity. Circulation. 2013;128:98-100.
77. Jay SM, Kurtagic E, Alvarez LM, de Picciotto S, Sanchez E, Hawkins JF, et al. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem. 2011;286:27729-40.
78. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99:8880-5. (Pubitemid 34693652)
79. Garcia-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol. 2005;289:H1153-60.
80. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-65. (Pubitemid 34546747)
81. Guma A, Martinez-Redondo V, Lopez-Soldado I, Canto C, Zorzano A. Emerging role of neuregulin as a modulator of muscle metabolism. Am J Physiol Endocrinol Metab. 2010;298:E742-50.
82. Jie B, Zhang X, Wu X, Xin Y, Liu Y, Guo Y. Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt and inhibiting mitochondrial permeability transition pore. Mol Cell Biochem. 2012;370:35-43.
83. Li J, Qiang O, Wang L. Effects of neuregulin on cardiac myocyte apoptosis and PI-3K signal transduction pathway in rapid pacing-induced heart failure in rhesus monkeys. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007;32:408-12.
84. Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, Holtz J. Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J Mol Cell Cardiol. 2005;38:485-93. (Pubitemid 40331939)
85. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res. 2007;313:1588-601. (Pubitemid 46589436)
86. Rentschler S, Zander J, Meyers K, France D, Levine R, Porter G, et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci U S A. 2002;99:10464-9.
87. Ruhparwar A, Er F, Martin U, Radke K, Gruh I, Niehaus M, et al. Enrichment of cardiac pacemaker-like cells: neuregulin-1 and cyclic AMP increase I(f)-current density and connexin 40 mRNA levels in fetal cardiomyocytes. Med Biol Eng Comput. 2007;45:221-7. (Pubitemid 46291446)
88. Ruhparwar A, Haverich A. Prospects for biological cardiac pacemaker systems. Pacing Clin Electrophysiol. 2003;26:2069-71. (Pubitemid 37433672)
89. Matsukawa R, Hirooka Y, Ito K, Sunagawa K. Inhibition of neuregulin-1/ErbB signaling in the rostral ventrolateral medulla leads to hypertension through reduced nitric oxide synthesis. Am J Hypertens. 2013;26:51-7.
90. Kalinowski A, Plowes NJ, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J. 2010;24:2567-75.
91. Hintsanen M, Elovainio M, Puttonen S, Kivimaki M, Raitakari OT, Lehtimaki T, et al. Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med. 2007;33:148-55. (Pubitemid 47289493)
92. • Safa RN, Peng XY, Pentassuglia L, Lim CC, Lamparter M, Silverstein C, et al. Neuregulin-1beta regulation of embryonic endothelial progenitor cell survival. Am J Physiol Heart Circ Physiol. 2011;300:H1311-9. This work demonstrates that a subpopulation of monocytes in the circulation that have been associated with cardiac repair respond to NRG with enhanced survival. Whether this set of cells is activated by NRG during cardiac injury/stress and mediates cardiac repair remains an open question.
93. Lok J, Sardi SP, Guo S, Besancon E, Ha DM, Rosell A, et al. Neuregulin-1 signaling in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29:39-43.
94. Li Q, Zhang R, Ge YL, Mei YW, Guo YL. Effects of neuregulin on expression of MMP-9 and NSE in brain of ischemia/reperfusion rat. J Mol Neurosci. 2009;38:207-15.
95. Panutsopulos D, Arvanitis DL, Tsatsanis C, Papalambros E, Sigala F, Spandidos DA. Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res. 2005;42:463-74. (Pubitemid 41527601)
96. Lok J, Zhao S, Leung W, Seo JH, Navaratna D, Wang X, et al. Neuregulin-1 effects on endothelial and blood-brain-barrier permeability after experimental injury. Transl Stroke Res. 2012;3:S119-24.
97. Marballi K, Quinones MP, Jimenez F, Escamilla MA, Raventos H, Soto-Bernardini MC, et al. In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation. J Mol Med (Berl). 2010;88:1133-41.
98. Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol. 2011;300:H931-42.
99. Kim JS, Choi IG, Lee BC, Park JB, Kim JH, Jeong JH, et al. Neuregulin induces CTGF expression in hypertrophic scarring fibroblasts. Mol Cell Biochem. 2012;365:181-9.
100. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-7.
101. Barisione C, Garibaldi S, Ghigliotti G, Fabbi P, Altieri P, Casale MC, et al. CD14CD16 monocyte subset levels in heart failure patients. Dis Markers. 2010;28:115-24.
102. Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56:593-9.
103. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133-45.
104. Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, et al. Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol. 2003;74:593-601. (Pubitemid 38040387)
105. Mograbi B, Rochet N, Imbert V, Bourget I, Bocciardi R, Emiliozzi C, et al. Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw. 1997;8:73-81. (Pubitemid 27189859)
106. Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, et al. Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis. Circ Res. 2009;105:500-10.
107. Okoshi K, Nakayama M, Yan X, Okoshi MP, Schuldt AJ, Marchionni MA, et al. Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation. 2004;110:713-7. (Pubitemid 39056271)
108. Watanabe T, Sato K, Itoh F, Iso Y. Pathogenic involvement of heregulin-beta(1) in anti-atherogenesis. Regul Pept. 2012;175:11-4.